Yaroslav Teper, PhD.
Senior Immuno-oncology Scientist
Senior Biomedical Scientist with an outstanding track record of innovation and discovery. Possesses expert skills in all facets of therapeutic discovery and project leadership across both traditional oncology and the cutting edge tumor immunology fields. Have successfully led development of both in-vivo and in-vitro disease models that have led to successful drug patents, immunotherapy protocols, biomarker discovery and disease classification. Successfully managed and directed a great deal of successful pre-clinical projects, which led to efficient and expedient outcomes. I believe my track record and experience will be a great addition to any ambitious and results oriented institution.
Riptide Biosciences, Vallejo, CA 2015 – present
Consultant Staff Scientist/Project Manager
Leading development of anti-cancer peptides and therapeutic antibodies
Develop in-vitro bioassays to test for efficacy of different peptides and therapeutic antibodies
Developing in-vivo models and radiological assays for optimal therapeutic screening results
Training and delegating to in-vitro and in-vivo technician teams
Surgery Branch(NCI/National Institutes of Health) Bethesda, MD 2010 – 2015
Senior Research Scientist (FTE level)
Discovered rare, novel pancreatic cancer-only expressing antigen that was used to develop novel anti-pancreatic chimeric antigen receptors (CARs) for engineered anti-tumor T-Cells
Led development of peptides that targeted tumor-associated macrophages, monocytes and dendritic cells which contribute to standard care tumor resistance
Successfully led the development of novel anti-metastatic pancreatic cancer compound that is currently being developed for Phase I studies
Discovered many biomarkers of immunotherapy resistance in refractive gastric and pancreatic cancer cell lines
Led development and utilization of xenotransplant and transgenic mouse models of pancreatic cancer for drug and immunotherapy development
Developed and utilized unique animal model of metastasis that can be tracked with
bioluminescence. This technique is now standard of practice in many NIH branches
Successfully led analysis of cancer stem cell biology with novel kinome screens
Utilized state-of-the art cell sorting techniques
Established over ten new pancreatic and GI cancer cell lines from freshly excised patient tissue
Utilized siRNA and various other plasmid transfection techniques to study roles of novel genes
in cancer stem cell biology.
Harvard Medical School, Boston, MA 2008 – 2009 Kirchstein NRSA Research Fellow
Molecular Biologist in the field of cancer-associated angiogenesis
Led development of shRNA knockdown and up-regulation assays using viral vectors
Culturing and genetic manipulation of HUVEC and mouse endothelial precursor cells that were
used in various established assays such as the matrigel vessel formation and Aortic ring assay.
Genetically manipulated a vast variety of cell lines with adenoviral and lentiviral vectors
University of Melbourne/Monash University, Melbourne, Australia 2002 – 2007 PhD Student/Post-Doc
Molecular Biologist and Electrophysiologist
Established a mouse model of Autosomal dominant frontal lobe epilepsy (ADNFLE) and successfully observed a novel phenotype that perfectly recapitulated the human condition
Gained expertise in manipulating bacterial plasmid vectors, transformation of bacterial and murine embryonic stem cells
Established a novel algorithm of pre-seizure EEG detection that is currently being employed by a device being developed by startup called Neurovista
AMGEN, Thousand Oaks, CA 2000-2002 Research Associate
Served as an analytical chemist for small molecule metabolism group
Used triple-quad HPLC/MS/MS systems to analyze pre-clinical drug metabolites from liver microsomes.
UCLA School of Medicine, Los Angeles, CA 1997-1999 Research Associate
HPLC technician in research pertaining to metabolism of anti-psychotic drugs
Led development of novel anti-metastasis drug named Metarrestin for treatment of
advanced stage pancreatic cancer. Devised a definitive mouse model to test for effectiveness of compounds for local and metastatic invasion of refractory pancreatic tumors.
Was a key team member in the discovery of new pancreatic cancer antigen (PSCA) that was successfully
utilized to engineer a novel tumor infiltrating lymphocyte technique.
Discovered novel pathways that are selectively toxic to cancer stem cells. Via subsequent array screens discovered five new novel, cancer stem cell specific therapeutic targets.
Developed four new peptides targeting tumor associated macrophages and dendritic cells. Inhibition of these cell types greatly enhanced standard care therapeutics on primary tumor.
Was the team lead to discovery of various biomarkers of cancer cell resistance to common small molecule and immunotherapy techniques.
Created endothelial cell lines that modified regulation of various candidate genes suspected of being
involved in pathological angiogenesis using both lentiviral and adenoviral vectors. Established a novel
role for fatty acid binding protein FABP4 in cancer associated angiogenesis
Created a transgenic mouse model of autosomal nocturnal frontal lobe epilepsy (ADNFLE) and
Identified a key phenotype( entitled the Dystonic arousal complex) that directly recapitulates the human
condition. This discovery helped to reclassify the mechanism of the disease.
Developed a mouse model (D1-Tox mouse) that mimicked the pathological destruction of
dopaminergic neurons on Parkinson's disease. Observed and quantified epileptic events in transgenic
animals using novel monitoring and electrophysiological systems.
PROFESSIONAL SKILLS AND SELECT INSTRUMENT EXPERTISE
Comprehensive in-vivo skills
Creating transgenic animals for both oncological and neurological themes
Working with vast lines of immune-compromised mouse strains
Designing and implementing in-vivo models for immunotherapy/small molecule/therapeutic peptide experiments
Surgeries (both orthotopic and autotopic)
Small animal radiology
Ultrasound (abdominal and thoracic)
Expertise in culturing a plethora of cell lines
96/48/24/6 -well plate assays
T-cells, B-cells, Macrophages/monocytes and dendritic cells
Epithelial and endothelial cells
Stem cell spheres in both adhesive and non-adhesive environments
Cancer cells (differentiated and mesenchymal)
In-vitro cancer cell assays including 3D cultures and
DNA Cloning Techniques
PCR techniques (including real time)
shRNA/siRNA knockdown techniques
Lentiviral/Adenoviral mediated cell manipulation
FACS sorting and analysis
Modern sequencing techniques
T-cell activity assays, ELISPOT
Cytokine (Interleukin) quantitation
Plethora of chip-based array techniques(Illumina technologies)
Agilent 1100 LC MSD Model G1946D Mass Spectrometer
Agilent 6400 Series Triple Quadrupole LC/MS
Agilent 6200 Series MALDI-TOF(Time of Flight) Instruments
All Waters, Shimadzu and Agilent HPLC pumps
Next Generation Sequencing and array instruments:
Illumina HiSeq family of sequencer
Illumina HiScan family of arrays reading systems
Full knowledge of HPLC operations(including PK/PD work-ups)
Vast Expertise in Mass Spectroscopy work
Both peptides and small molecules
Single, Triple and MALDI-TOF Mass Spec. Instrument knowledge
Computer Literacy/Analytical Software
Full expertise in MS Office (eg. Word, PowerPoint and Excel)
PK/PD analysis software
Protein and DNA analysis programs (eg. DNA Star)
Full knowledge of various Linux-based DNA genome sequence analysis
Data Analysis with MATLAB
Biorad CFX96 and CFX384 thermocyclers(for both PCR and qPCR)
Labnet MultiGene gradient thermocyclers
In-Vivo Imaging Instrumentation:
In-vivo bio-luminescence instruments
U-SPECT II/CT combinational imager
VEVO 2100 LAZR Laser/Doppler Imaging System(Ultrasound)
IVIS SpectrumCT Preclinical In Vivo Imaging System(CT/IVIS combo)
GentleMACS Tissue dissociation system
BD FacsCalibur, Canto and FACSARIA family of sorters(Up to 10 lasers)
Mammalian Cell Pulldown systems:
1991-1996 California State University,
Northridge (GPA: 3.4) BS Biochemistry
1998-2000 University of California,
Los Angeles (GPA: 3.6) MS Physiology
2002-2006 Monash University (GPA: N/A) Ph. D. Genetics
Maragun, J, Teper Y, et al. Metarrestin, a novel approach to metastasis. Collaborative NCI/NCATS clinical research program. NeXT/NCI clinical grant for Phase I clinical trial. In Progress. $2 million.
Teper Y, Sorber R, Ray S, Davies S, Waterfall JJ, Pflicke H, Wunderlich J, Meltzer PS, Avital I, Schrump DS, Rudloff U. Whole genome sequencing of a newly established pancreatic cancer line identifies novel somatic mutation(G2587A) in axon guidance receptor plexin A1 as enhancer of proliferation and invasion. PLoS One 2014, (manuscript under review).
Schaub N, Teper Y, Bapiro TE, Richards FM, Pflicke H, Sorber R, Avital I, Schrump DS, Jodrell DI, Rudloff U. Inhibition of transforming growth factor-β signaling in combination with gemcitabine effectively suppresses tumor growth in genetically engineered mouse models of pancreas cancer: modulation of drug delivery is genotype-driven and implies alterations of adoptive immunity, Cancer Res, 2014 (manuscript under review)
Abate-Daga D1, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A novel chimeric antigen receptor against PSCA mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014 Apr 2.
Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 2009 Jul 22
Cannata DJ, Finkelstein DI, Gantois I, Teper Y, Drago J, West .Altered fast- and slow-twitch muscle fibre characteristics in female mice with a (S248F) knock-inmutation of the brain neuronal nicotinic acetylcholine receptor. J Muscle Res Cell Motil. 2009;30(1-2):73-83
Moses D., Teper Y., Drago J., Gantois I., Finkelstein DI., Horne MK., Fetal Striatum and ventral Mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in-vitro and nigro-striatal system in-vivo: Possible contribution of injury-derived signals. Neuroscience 2008; Jun 23;154(2):606-20
Teper Y, Whyte D, Cahir E, Lester HA, Grady SR, Marks MJ, Cohen BN, Fonck C, McClure-Begley T, McIntosh JM, Labarca C, Lawrence A, Chen F, Gantois I, Davies PJ, Petrou S, Murphy M, Waddington J, Horne MK, Berkovic SF, Drago J. Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation. J Neurosci. 2007 Sep 19;27(38):10128-42
Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, Teper Y, Jupp B, Ziebell J, Morganti-Kossmann CM, O'Brien TJ, Nally R, Schütz G, Waddington J, Egan GF, Drago J. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4182-7
Moses D, Teper Y, Gantois I, Finkelstein DI, Horne MK, Drago J. Murine embryonic EGF-responsive ventral mesencephalic neurospheres display distinct regional specification and promote survival of dopaminergic neurons. Exp Neurol. 2006 May;199(1):209-21
Aravagiri M, Teper Y, Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos. 1999 Nov;20(8):369-77
Wang C, Frankowski K, Teper Y, Samarjit P, Schoenen F, Southall N, Wei S, Titus S, Griner L, Dextras C, Sultan J, Kandela I, Lewandowska M, Wen YP, Norton J, Kang JS, Mazar A, Zhang W, Aubé J, Ferrer M, Rudloff U, Marugan JJ, Huang A. Metarrestin effectively disassembles PNCs and inhibits metastasis. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA
Sorber R, Teper Y, Schaub NP, Zacharia A, Jaynes J, Yates C, Martin G, Rudloff U. The Novel immunomodulatory 10-mer peptide RP-182 is an effective mediator of tumor growth suppression via alteration of tumor associated macrophage (TAM) phenotype in a pancreas cancer xenotransplant. AACR 106th Annual Meeting 2015; April 2015; April 18-22, 2015, Philadelphia, PA
941 Railroad Ave.
Vallejo, CA 94592
Nicholas P. Restifo, M.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-5762
Bethesda, MD 20892
Juan Jose Marugan, Ph.D.
Group Leader, NIH Chemical Genomics Center National Center for Advancing Translational Sciences National Institutes of Health
9800 Medical Center Drive, Bldg B
Rockville, MD 20850
Daniel Abate-Daga, PhD.
Morsani College of Medicine
University of South Florida
12902 Magnolia Drive MRC 2067G
Tampa, FL 33612-9416
Sui Huang MD, PhD
Department of Cell and Molecular Biology
Northwestern University Feinberg School of Medicine
303 E. Chicago Ave, Ward building Rm:11-240
Chicago IL, 60611
Marc Ferrer, PhD
9800 Medical Center Drive
Rockville, MD 20850
Cell Phone: 240-***-****